MicroRNA Modulation in Venous Thrombosis

MicroRNAs are endogenous, small non-coding RNAs that orchestrate post-transcriptional gene regulation and have emerged as pivotal modulators of venous thrombosis. Aberrant microRNA expression alters endothelial cell integrity, coagulation factor synthesis and the reparative capacity of endothelial progenitor cells, thereby influencing thrombus initiation, propagation and resolution. In deep vein thrombosis, distinct microRNA signatures have been linked to impaired angiogenesis, enhanced apoptosis and sustained inflammation within the venous wall. Circulating microRNAs offer a minimally invasive window into the haemostatic state, with potential to predict thrombosis risk, recurrence and therapeutic response. Advances in high-throughput profiling, functional assays and animal models have elucidated microRNA-mediated control of key targets such as tissue factor and components of the fibrinolytic system. By integrating mechanistic insight with biomarker discovery, microRNA modulation holds promise both for novel diagnostic platforms and for tailored interventions that restore vascular homeostasis and promote safe thrombus resolution.

Research from Nature Portfolio

No recent Nature Portfolio content available.

MicroRNA Modulation in Venous Thrombosis publication trend

The graph below shows the total number of articles in microrna modulation in venous thrombosis across all publications each year (not limited to Nature Index journals).

Technical terms

MicroRNA: Small non-coding RNA molecules that regulate gene expression by binding to complementary messenger RNA, inducing translational repression or RNA degradation.

Endothelial progenitor cell (EPC): Circulating cells capable of differentiating into endothelial cells and promoting blood vessel repair and angiogenesis.

Deep vein thrombosis (DVT): The formation of a blood clot within the deep veins, most commonly in the legs, which may obstruct venous return and risk embolisation.

Venous thromboembolism (VTE): A clinical syndrome encompassing deep vein thrombosis and pulmonary embolism, arising when a venous clot dislodges and migrates to the lungs.

Tissue factor (TF): A transmembrane glycoprotein that initiates the extrinsic coagulation cascade upon vascular injury, driving thrombin generation.

Biomarker: A measurable biological parameter that indicates a physiological or pathological state or predicts therapeutic response.

References

1. Non-coding RNAs regulating endothelial progenitor cells for venous thrombosis: promising therapy and innovation. Stem Cell Research & Therapy (2024).
2. Plasma microRNA Environment Linked to Tissue Factor Pathway and Cancer-Associated Thrombosis: Prognostic Significance in Ovarian Cancer. Biomolecules (2024).
3. Association of recurrent venous thromboembolism and circulating microRNAs. Clinical Epigenetics (2019).
4. MiR‐205 promotes endothelial progenitor cell angiogenesis and deep vein thrombosis recanalization and resolution by targeting PTEN to regulate Akt/autophagy pathway and MMP2 expression. Journal of Cellular and Molecular Medicine (2019).